Adv Ther (2017) 34:1966–1975 DOI 10.1007/s12325-017-0580-1 ORIGINAL RESEARCH Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial . . . . Arrigo F. G. Cicero Federica Fogacci Marilisa Bove Maddalena Veronesi . . Manfredi Rizzo Marina Giovannini Claudio Borghi Received: May 28, 2017 / Published online: July 7, 2017 The Author(s) 2017. This article is an open access publication Moreover, ALT (-27.7%, P\0.001), AST ABSTRACT (-13.8%, P = 0.004), and serum uric acid (-12.3%, P = 0.005) were reduced by the tested Introduction: There is a growing interest in nutraceutical compound both compared to nutraceuticals improving cardiovascular risk randomization and to placebo, which did not factor levels and related organ damage. affect these parameters (P\0.01 for all). Methods: This double-blind, placebo-controlled Regarding the hemodynamic parameters, there randomized clinical trial aims to compare the was a decrease of systolic blood pressure effect of a combined nutraceutical containing (-5.6%) with the active treatment not observed red yeast rice (10 mg), phytosterols (800 mg), and with placebo (P\0.05 vs baseline and placebo) L-tyrosol (5 mg) on lipid proﬁle, blood pressure, and endothelial reactivity improved, too endothelial
Advances in Therapy – Springer Journals
Published: Jul 7, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera